Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
22.28 (1y: +276%)
Market Cap 1.45 B P/E(ttm) 44.10
Enterprise Value 1.36 B P/B 17.16
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 9.593
SNTS's Cash to Debt is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SNTS: 9.593 )
SNTS' s 10-Year Cash to Debt Range
Min: 5.2   Max: No Debt
Current: 9.59
Equity to Asset 0.39
SNTS's Equity to Asset is ranked lower than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. SNTS: 0.39 )
SNTS' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.7
Current: 0.39
-0.02
0.7
Interest Coverage 65.5
SNTS's Interest Coverage is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SNTS: 65.5 )
SNTS' s 10-Year Interest Coverage Range
Min: 12   Max: No Debt
Current: 65.5
F-Score: 6
Z-Score: 10.6
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 9.30
SNTS's Operating margin (%) is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. SNTS: 9.30 )
SNTS' s 10-Year Operating margin (%) Range
Min: -6148.8   Max: 19.8
Current: 9.3
-6148.8
19.8
Net-margin (%) 8.5
SNTS's Net-margin (%) is ranked higher than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. SNTS: 8.5 )
SNTS' s 10-Year Net-margin (%) Range
Min: -6045.6   Max: 18.6
Current: 8.5
-6045.6
18.6
ROE (%) 22.4
SNTS's ROE (%) is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. SNTS: 22.4 )
SNTS' s 10-Year ROE (%) Range
Min: -288.4   Max: 68.5
Current: 22.4
-288.4
68.5
ROA (%) 11.3
SNTS's ROA (%) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. SNTS: 11.3 )
SNTS' s 10-Year ROA (%) Range
Min: -103.4   Max: 24.4
Current: 11.3
-103.4
24.4
Revenue Growth (%) 2.2
SNTS's Revenue Growth (%) is ranked higher than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. SNTS: 2.2 )
SNTS' s 10-Year Revenue Growth (%) Range
Min: -32.4   Max: 146.6
Current: 2.2
-32.4
146.6
EBITDA Growth (%) -11.2
SNTS's EBITDA Growth (%) is ranked lower than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. SNTS: -11.2 )
SNTS' s 10-Year EBITDA Growth (%) Range
Min: -39.5   Max: -11.2
Current: -11.2
-39.5
-11.2
EPS Growth (%) -15.9
SNTS's EPS Growth (%) is ranked lower than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. SNTS: -15.9 )
SNTS' s 10-Year EPS Growth (%) Range
Min: -39.9   Max: -15.9
Current: -15.9
-39.9
-15.9
» SNTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SNTS Guru Trades in Q2 2012

Steven Cohen 3,540,929 sh (+65.75%)
Jim Simons 1,355,443 sh (+21.81%)
» More
Q3 2012

SNTS Guru Trades in Q3 2012

Jim Simons 1,606,643 sh (+18.53%)
Steven Cohen 3,993,017 sh (+12.77%)
» More
Q4 2012

SNTS Guru Trades in Q4 2012

Paul Tudor Jones 12,600 sh (New)
Jim Simons 2,321,938 sh (+44.52%)
Steven Cohen 3,351,290 sh (-16.07%)
» More
Q1 2013

SNTS Guru Trades in Q1 2013

Jim Simons 2,548,943 sh (+9.78%)
Paul Tudor Jones 11,800 sh (-6.35%)
Steven Cohen 34,591 sh (-98.97%)
» More
» Details

Insider Trades

Latest Guru Trades with SNTS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-09-30 Sold Out 0.0013%$2.49 - $3.39 $ 22.28626%0
George Soros 2011-06-30 Add 46.35%$3.03 - $3.48 $ 22.28592%28100
George Soros 2011-03-31 New Buy$3.14 - $3.69 $ 22.28571%19200
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 44.10
SNTS's P/E(ttm) is ranked higher than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 20.85 vs. SNTS: 44.10 )
SNTS' s 10-Year P/E(ttm) Range
Min: 3.45   Max: 648
Current: 44.1
3.45
648
P/B 17.00
SNTS's P/B is ranked lower than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SNTS: 17.00 )
SNTS' s 10-Year P/B Range
Min: 2.31   Max: 18.71
Current: 17
2.31
18.71
P/S 6.40
SNTS's P/S is ranked higher than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. SNTS: 6.40 )
SNTS' s 10-Year P/S Range
Min: 0.49   Max: 16.62
Current: 6.4
0.49
16.62
PFCF 57.20
SNTS's PFCF is ranked higher than
71% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. SNTS: 57.20 )
SNTS' s 10-Year PFCF Range
Min: 3.39   Max: 167
Current: 57.2
3.39
167
EV-to-EBIT 31.3
SNTS's EV-to-EBIT is ranked higher than
51% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. SNTS: 31.3 )
SNTS' s 10-Year EV-to-EBIT Range
Min: 1.2   Max: 116.1
Current: 31.3
1.2
116.1

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 101.3
SNTS's Price/Net Cash is ranked higher than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. SNTS: 101.3 )
SNTS' s 10-Year Price/Net Cash Range
Min: 2.9   Max: 65.4
Current: 101.3
2.9
65.4
Price/Net Current Asset Value 50.6
SNTS's Price/Net Current Asset Value is ranked higher than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. SNTS: 50.6 )
SNTS' s 10-Year Price/Net Current Asset Value Range
Min: 6.8   Max: 47.6
Current: 50.6
6.8
47.6
Price/Tangible Book 22.3
SNTS's Price/Tangible Book is ranked higher than
85% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. SNTS: 22.3 )
SNTS' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 11.9
Current: 22.3
2.6
11.9
Price/DCF (Projected) 13
SNTS's Price/DCF (Projected) is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. SNTS: 13 )
SNTS' s 10-Year Price/DCF (Projected) Range
Min: 9   Max: 9
Current: 13
Price/Median PS Value 3.6
SNTS's Price/Median PS Value is ranked higher than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. SNTS: 3.6 )
SNTS' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 4.5
Current: 3.6
0.4
4.5
Price/Graham Number 9.4
SNTS's Price/Graham Number is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. SNTS: 9.4 )
SNTS' s 10-Year Price/Graham Number Range
Min: 1.7   Max: 4.7
Current: 9.4
1.7
4.7
Earnings Yield (Greenblatt) 3.20
SNTS's Earnings Yield (Greenblatt) is ranked higher than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. SNTS: 3.20 )
SNTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 86.3
Current: 3.2
0.9
86.3
Forward Rate of Return (Yacktman) 0.16
SNTS's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. SNTS: 0.16 )
SNTS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -23.9   Max: 0.3
Current: 0.16
-23.9
0.3

Business Description

Santarus, Inc. was incorporated in California in December 1996 and reincorporated in Delaware in July 2002. It is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other targeted physicians. The Company's commercial organization is currently promoting Zegerid (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension, which are proprietary formulations that combine omeprazole, which is a proton pump inhibitor, or PPI, and an antacid. The Company developed these products as the first immediate-release oral PPIs for the U.S. prescription market, and they have been approved by the U.S. Food and Drug Administration, or FDA, to treat or reduce the risk of a variety of upper gastrointestinal, or GI, diseases and disorders, including gastroesophageal reflux disease, or GERD. The Company's Zegerid products are based on patented technology and utilize antacids, which raise the gastric pH and thus protect the PPI, omeprazole, from acid degradation in the stomach, allowing the omeprazole to be quickly absorbed into the bloodstream and to provide continued acid control. The Company's commercial organization also promotes Glumetza (metformin hydrochloride extended release tablets) prescription products in the U.S. The Company is developing two product candidates targeting lower GI conditions under the terms of a strategic collaboration that it entered into with Cosmo Technologies Limited, or Cosmo. The product candidates utilize Cosmo's patented MMX technology, which is a proprietary multi-matrix system that is designed to deliver a drug substance to the colon. The Company has licensed exclusive rights to Schering-Plough HealthCare Products, Inc., or Schering-Plough, a subsidiary of Merck & Co., Inc., to develop, manufacture and sell Zegerid OTC products in the lower dosage strength of 20 mg of omeprazole in the U.S. and Canada. It own or have rights to various trademarks, copyrights and tradenames used in business, including the following: Santarus, Zegerid, Glumetza, Cycloset, Fenoglide, MMX and MMX Multi-Matrix System and Rhucin. The pharmaceutical industry is subject to intense competition. Governmental authorities in the U.S. and other countries extensively regulate the testing, manufacturing, labeling, storage, recordkeeping, advertising, promotion, export, marketing and distribution, among other things, of pharmaceutical products.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:TW4A.Germany
» More Articles for SNTS

Headlines

Articles On GuruFocus.com
Santarus Inc. Reports Operating Results (10-K) Mar 04 2011 
Santarus Inc. Reports Operating Results (10-Q) Nov 09 2010 
Santarus Inc. Reports Operating Results (10-Q) Aug 03 2010 
Santarus Inc. Reports Operating Results (10-Q) May 07 2010 
Quantitative Screens: Good First Step…. but Keep Digging. Mar 25 2010 
Santarus Inc. Reports Operating Results (10-Q) Nov 05 2009 
Santarus Inc. Reports Operating Results (10-Q) Aug 04 2009 
Santarus Inc. Reports Operating Results (10-Q) May 07 2009 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial